Grifols

Grifols Current Liabilities

The Current Liabilities of Grifols (GRF.MC) as of Sep 17, 2026 is 2.02 B EUR. In the previous year, Current Liabilities was 2.87 B EUR — a change of -29.75% (lower).

Current Liabilities

2.02 BEUR

YoY

-29.75%

Last updated:

Current Liabilities of Grifols is 2026 2.02 B EUR. Current Liabilities of Grifols was 2025 2.87 B EUR. It decreases by -29.75% lower compared to the previous year.

The Grifols Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
1.62 B EUR
Jan 1, 2019
1.80 B EUR
Jan 1, 2020
1.81 B EUR
Jan 1, 2021
6.09 B EUR
Jan 1, 2022
2.85 B EUR
Jan 1, 2023
3.16 B EUR
Jan 1, 2024
2.87 B EUR
Jan 1, 2025
2.02 B EUR
The Grifols Current Liabilities history
YEARCurrent LiabilitiesYoY
2.02 BEUR-29.75%
2.87 BEUR-9.05%
3.16 BEUR+10.79%
2.85 BEUR-53.17%
6.09 BEUR+237.18%
1.81 BEUR+0.53%
1.80 BEUR+10.99%
1.62 BEUR+35.93%
1.19 BEUR-12.41%
1.36 BEUR+3.95%
1.31 BEUR+6.01%
1.23 BEUR+20.53%
1.02 BEUR+21.55%
842.33 MEUR-2.19%
861.21 MEUR+34.79%
638.91 MEUR+47.17%
434.14 MEUR-7.77%
470.71 MEUR-4.00%
490.35 MEUR+16.50%
420.89 MEUR+19.60%
351.92 MEUR-26.68%
479.96 MEUR+63.69%
293.21 MEUR-11.25%
330.39 MEUR+46.55%
225.45 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Grifols Stock analysis

What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grifols stock

Current Liabilities of Grifols is 2.02 B EUR in 2026.

Current Liabilities of Grifols changed from 2.87 B EUR to 2.02 B EUR, representing a -29.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Grifols since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Grifols historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Grifols

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Grifols